GENOPTIC
Clinical safety rating: caution
Comprehensive clinical and safety monograph for GENOPTIC (GENOPTIC).
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
| Metabolism | Not appreciably metabolized; excreted unchanged in urine. |
| Excretion | Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%. |
| Half-life | 2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours. |
| Protein binding | 20-30% bound to serum albumin. |
| Volume of Distribution | 0.2-0.3 L/kg; low Vd indicates limited tissue distribution (mainly extracellular fluid). |
| Bioavailability | Oral: 60-80% (first-pass effect); ophthalmic: negligible systemic absorption (≤1%). |
| Onset of Action | Intravenous: immediate; oral: 1-2 hours; topical (ophthalmic): 30 minutes. |
| Duration of Action | Intravenous: 6-8 hours; oral: 8-12 hours; topical: 4-6 hours; clinical effect persists while drug levels above MIC. |
| Molecular Weight | 477.59 |
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required for ophthalmic use due to minimal systemic absorption. |
| Liver impairment | No dose adjustment required for ophthalmic use due to minimal systemic absorption. |
| Pediatric use | Same as adult dosing: 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially. |
| Geriatric use | Same as adult dosing; no specific adjustment needed for ophthalmic use. |
| 1st trimester | Genoptic (gentamicin ophthalmic) is generally avoided during the first trimester due to potential risks, but systemic absorption after topical administration is minimal. |
| 2nd trimester | Use during the second trimester is acceptable if clearly needed, as absorption is low and risk is minimal. |
| 3rd trimester | Use during the third trimester is acceptable if clearly needed, with monitoring for potential effects. |
Clinical note
Comprehensive clinical and safety monograph for GENOPTIC (GENOPTIC).
| Placental transfer | Gentamicin crosses the placenta when administered systemically, but topical ocular administration results in negligible systemic exposure and minimal placental transfer. |
| Breastfeeding | Topical ocular gentamicin is unlikely to be absorbed systemically in significant amounts and is considered compatible with breastfeeding. |
■ FDA Black Box Warning
Not applicable (no FDA black box warnings for Genoptic).
| Serious Effects |
Hypersensitivity to gentamicin or any aminoglycosideViral or fungal ocular infections
| Precautions | Prolonged use may result in overgrowth of nonsusceptible organisms including fungi., Discontinue use if sensitization or irritation occurs., Monitor for signs of systemic absorption, especially in patients with renal impairment., Avoid prolonged use due to risk of secondary infections. |
| Food/Dietary | None reported with ophthalmic use. No dietary restrictions. |
| Clinical Pearls |
Loading safety data…
| Lactation Rating | L1 (Safe) |
| Teratogenic Risk | Category C: No adequate studies in pregnant women. In animal studies, gentamicin (the active ingredient in GENOPTIC) has been associated with fetal renal toxicity and ototoxicity when administered systemically at high doses. Topical ophthalmic use results in minimal systemic absorption, but risk cannot be excluded. Avoid use during first trimester unless clearly needed. |
| Fetal Monitoring | Monitor for signs of hypersensitivity or local irritation. No specific fetal monitoring required with topical ophthalmic use due to minimal systemic absorption. |
| Fertility Effects | No known effect on fertility from topical ophthalmic gentamicin. Systemic aminoglycosides may impair fertility in animal studies at high doses, but clinical relevance for topical use is negligible. |
| GENOPTIC (gentamicin sulfate ophthalmic solution) is an aminoglycoside antibiotic for ocular infections. Ensure proper diagnosis via culture and sensitivity. Use with caution in patients with renal impairment or myasthenia gravis due to potential systemic absorption. Monitor for hypersensitivity reactions; discontinue if keratitis or corneal ulceration occurs. Avoid prolonged use to prevent superinfection with resistant organisms, including fungi. Not for intraocular injection. |
| Patient Advice | Wash hands before and after use. · Tilt head back, pull down lower eyelid, and apply 1-2 drops into the conjunctival sac. · Avoid touching the dropper tip to any surface, including the eye, to prevent contamination. · Do not wear contact lenses during treatment unless directed by your doctor. · Complete the full course of therapy even if symptoms improve. · Report any signs of allergic reaction, such as rash, itching, or swelling of the eyes/face. · May cause temporary blurred vision; avoid driving or operating machinery until vision clears. |